吉西他滨联合诺维本治疗晚期乳腺癌的临床观察

目的:观察吉西他滨(健择)联合诺维本方案(GN方案)治疗蒽环类或紫杉类耐药性晚期乳腺癌的疗效与安全性。方法:39例对蒽环类或紫杉类耐药性晚期乳腺癌患者,接受GEM1000mg/m2静滴,第1、8天,NVB25mg/m2,静滴,第1、8天,每21天为1周期,至少应用2周期。以WHO标准评价疗效和毒性。结果:39例患者中,CR2例(5.1%),PR18例(46.2%),SD11例(28.2%),PD8例(20.5%),RR为51.3%。中位缓解期7.9个月(4～23个月)。主要不良反应为骨髓抑制、消化道反应,均为可逆性。结论:GP方案治疗蒽环类或紫杉类耐药性晚期乳腺癌疗效较好,毒性反应可以耐受,是二线治疗蒽环类或紫杉类耐药性晚期乳腺癌的有效解救方案。     

TRAIL-DR4启动子区基因多态性与肺癌易感性的相关性研究

[目的]初步探讨TRAIL死亡受体4（DR4）基因多态性与肺癌易感性的关系。[方法]采用PCR-RFLP技术,对92例肺癌患者和92例健康对照者的DR4基因启动子区的-972C/T和-397G/T多态性位点基因型进行检测。以非条件Logistic回归校正混杂因素进行相关性分析。[结果]TRAIL-DR4基因-972C/T位点多态性与肺癌易感性无明显相关性;在吸烟≥20年的人群中含有-397G/T位点T等位基因（GT＋TT）比GG纯合基因型的肺癌发病风险增加（OR=3.462,95%CI：1.222～9.811,P=0.019）。[结论]DR4基因多态性与肺癌的易感性间存在一定的关系。     

尼妥珠单抗联合DCF方案治疗晚期胃癌1例

<正>随着新的化疗药物的不断出现,晚期胃癌的化疗已经具有较多的选择。但是,无论是在近期疗效还是在远期生存期上,其结果尚未能令人满意。靶向表皮生长因子受体(EGFR)药物的问世,使多种实体肿瘤的治疗效果得到了明显的提高。我科采     

Effect of Feitai Capsule(肺泰胶囊) on Quality of Life and Progression-Free Survival of Patients with Unresectable Non-Small Cell Lung Cancer

<正>Objective:To examine the effect of a Chinese medicinal herbal formula(Feitai Capsule,肺泰胶囊) on the quality of life(QOL) and progression-free survival(PFS) of patients with unresectable non-small cell lung cancer(NSCLC).Methods:Sixty-two patients were randomly divided into the treatment group(31 cases) and the control group(31 cases).For the treatment group,4 capsules(1.2 g/capsule) of Feitai Capsule were administered 3 times a day after meals for 3 weeks;then no drug was administered for 1 week.This schedule was continued for at least 3 more cycles(12 weeks totally).If there were no obvious toxic reactions,the treatment was extended.The patients were evaluated at least once every 8 weeks until progressive disease(PD). For the control group,the regular follow-up and evaluation were performed at least once every 8 weeks until PD.Clinical symptoms,objective response,physical constitution and energy,QOL,and PFS were evaluated regularly.Analysis of variance(ANOVA),a non-parametric test,and analysis of covariance were used to compare clinical features,amelioration of clinical symptoms,physical constitution and energy,and QOL.Kaplan-Meier analysis was used to compare the two-group PFS.Results:Sixty patients finished the final evaluation, with 30 patients in each group.Baseline characters between groups were not significantly different(P0.05). The control group had a 36.7%improvement in clinical symptoms,while the treatment group had a 73.3% improvement.This difference was statistically significant(Z=-2.632,P=0.008).The control group had a 26.7% improvement in the Karnofsky performance status(KPS),while the treatment group had a 53.4%improvement. This was also significantly different(Z=-2.182,P=0.029).A comparative analysis indicated a positive correlation (r=0.917,P0.001).Compared with the control group,QOL in the treatment group was significantly improved, except in the social/family condition and doctor-patient relationship indicators.The PFS of the treatment group and control group were 6.23 months and 4.67 months,respectively(P=0.048).Conclusion:Feitai Capsule,a Chinese medicinal herbal treatment could improve the QOL and extend the PFS of the unresectable NSCLC patients.     

作为基因转移载体的乙肝病毒衣壳的制备及其功能的初步鉴定

目的〖HT5"SS〗： 构建具有肝脏靶向性的乙型肝炎病毒衣壳基因转移载体。〖HT5W〗方法: 〖HT5"SS〗采用PEG 8 000病毒浓缩法提取HepG 2.2.15细胞上清液中的乙型肝炎病毒,用β丙内酯法制备乙型肝炎病毒衣壳,用它包裹5.3kb的绿色荧光蛋白质粒以测试其装载能力,并用ELISA法、PCR法、SDS聚丙烯酰胺凝胶电泳、透射电镜等对它进行定量、定性研究,最后将其转染HepG 2细胞,通过荧光显微镜观察绿色荧光蛋白表达情况,通过流式细胞仪检测细胞发光率。〖HT5W〗结果: 〖HT5"S     

EWS—FLI1介导DTA基因在尤文肉瘤移植瘤裸鼠模型体内特异表达研究

尤文肉瘤是一种好发于青少年的恶性肿瘤，易在患病早期出现转移。尽管常规治疗方案可改善患者五年生存率。但在出现复发或转移的情况下，这部分患者的治疗仍较为困难。肿瘤基因治疗是目前比较活跃的领域，倍受人们的关注。恶性肿瘤基因治疗的研究为患者带来了新的希望。经研究证实，95％以上的尤文肉瘸家族中有染色体易位现象。即t（11；22）（q24；q12），形成EWS—FLI1融合基因。此融合基因只存在于肿瘤组织中，并且具有很强的转录。激活作用，可促进其下游特定基因的高表达。该融合基因的存在为尤文肉瘤基因治疗提供了一个重要线索。     

小剂量化疗治疗高龄晚期胃癌21例

[目的]观察小剂量氟尿嘧啶(5-Fu)与顺铂(DDP)、羟基喜树碱(HCPT)组成的FDH方案静脉给药治疗高龄晚期胃癌的临床疗效。[方法]治疗组21例,给予FDH方案:CF100mg/d,静脉滴注,第1～5天;5-Fu250mg/d,持续静脉滴注4h,第1～5天;DDP10mg/d,静脉滴注,第1～5天;HCPT5mg/d,静脉滴注,第l～5天。对照组33例,给予FOLFOX4方案:奥沙利铂130mg/m2,静脉滴注,第1天;亚叶酸钙200mg/m2,静脉滴注,第1、2天;5-Fu400mg/m2,静脉滴注,第1天,接着以5-Fu600mg/(m2·d),持续泵入48h;每28天为1个疗程。化疗2个疗程后评价疗效及不良反应。[结果]FDH方案组21例,CR1例,PR9例,NC7例,PD5例,有效率(CR PR)47.6%。中位生存期10.3个月。FOLFOX4方案组33例,CR2例,PR14例,NC10例,PD7例,有效率(CR PR)48.5%,中位生存期10.6个月,两组疗效无显著性差异(P>0.05)。两组主要不良反应均为白细胞减少和胃肠道反应。FDH组Ⅲ～Ⅳ度的白细胞下降(4.76%)及胃肠道反应(0)均较FOLFOX4组(18.18%、12.12%)低(P<0.05)。[结论]小剂量DDP、HCPT联合5-Fu持续静脉滴注是治疗高龄晚期胃癌的有效、安全的方案。     

含EWS-FLI1结合序列的DTA载体对报告基因表达抑制的研究

目的 研究含尤文家族肿瘤EWS-FLI1结合序列的DTA载体对报告基因表达的抑制作用.方法 构建含有EWS-FLI1结合序列和白喉毒素A链基因的表达载体pS2-DTA.共同转染不同剂量梯度的pS2-DTA和pS2到尤文肉瘤细胞和对照细胞,检测荧光强度.结果 每增加一个pS2-DTA剂量梯度,在尤文肉瘤细胞中都可以检测到虫荧光素酶的表达显著降低,而在对照细胞中这种作用却不明显;在同一个pS2-DTA剂量梯度下,虫荧光素酶在尤文肉瘤细胞的表达都显著高于非尤文肉瘤细胞.结论 pS2-DTA转染可以抑制尤文肉瘤细胞内其它基因表达.